Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645591 | 0.93 | ERCC1 (0.47) | ERCC1FEN1ERCC4ADORA2BADORA2A | |
| SCHEMBL6645274 | 0.90 | ERCC1 (0.57) | ERCC1FEN1ERCC4HSP90AA1HSP90AB1 | |
| SCHEMBL6651068 | 0.84 | ERCC1 (0.52) | ERCC1FEN1ERCC4SMN1; SMN2 | |
| SCHEMBL6649380 | 0.83 | ERCC1 (0.54) | ERCC1FEN1ERCC4MCHR1SMN1; SMN2 | |
| SCHEMBL1150767 | 0.76 | KCNE1 (0.49) | PRKAA2HSP90AA1HSP90AB1MCHR1HRH3 | |
| SCHEMBL6644307 | 0.76 | KDM4E (0.42) | ERCC1FEN1ERCC4SMN1; SMN2 | |
| SCHEMBL6645792 | 0.74 | ERCC1 (0.52) | ERCC1FEN1ERCC4ADORA2AHSP90AA1 | |
| SCHEMBL6884591 | 0.74 | ERCC1 (0.50) | ERCC1FEN1ERCC4ADORA2ASMN1; SMN2 | |
| SCHEMBL6885131 | 0.72 | ERCC1 (0.46) | ERCC1FEN1ERCC4ADORA2AADORA1 | |
| SCHEMBL5765798 | 0.71 | TP53 (0.44) | ERCC1FEN1ERCC4HRH3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | claimed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | ERCC1 1473/4885FEN1 292/4885ERCC4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.